Quality of Life in the Trastuzumab for Gastric Cancer Trial. (20th June 2014)

• Record Type: Journal Article
• Authors: Satoh, Taroh; Bang, Yung-Jue; Gotovkin, Evgeny A.; Hamamoto, Yasuo; Kang, Yoon-Koo; Moiseyenko, Vladimir M.; Ohtsu, Atsushi; Van Cutsem, Eric; Al-Sakaff, Nedal; Urspruch, Alexa; Hill, Julie; Weber, Harald A.; Chung, Hyun-Cheol
• Is Part Of: Oncologist. Volume 19:Number 7(2014)
• Page Start: 712
• Page End: 719
• Publication Date: 2014-06-20
• Subjects: Chemotherapy -- Gastric cancer -- HER2 -- Quality of life -- Trastuzumab; Oncology -- Periodicals; Tumors -- Periodicals; Cancérologie -- Périodiques; Tumeurs -- Périodiques; Oncology; Tumors; Neoplasms; Electronic journals; Periodicals; Periodicals; 616.994
• DOI: 10.1634/theoncologist.2014-0058
• Languages: English
• ISSNs: 1083-7159

Abstract

Abstract: Background: The Trastuzumab for Gastric Cancer phase III trial demonstrated that combining trastuzumab with chemotherapy significantly improved overall survival compared with chemotherapy alone in HER2-positive advanced gastric or gastroesophageal junction cancer. We report health-related quality of life (HRQoL) and quality-adjusted time without symptoms of disease or toxicity (Q-TWiST) results from this trial. Patients and Methods: Patients were randomized to receive six cycles of chemotherapy given every 3 weeks (capecitabine or fluorouracil, plus cisplatin) either alone or combined with administration of trastuzumab every 3 weeks until disease progression. At each clinical visit, HRQoL was assessed using two European Organization for Research and Treatment of Cancer quality of life questionnaires, QLQ-C30 and QLQ-STO22. Q-TWiST methodology was applied retrospectively using the clinical data and utility coefficients. Results: Trastuzumab plus chemotherapy prolonged time to 10% definitive deterioration in all QLQ-C30 and QLQ-STO22 scores, including QLQ-C30 global health status versus chemotherapy alone, from 6.4 months to 10.2 months. In addition, trastuzumab plus chemotherapy extended Q-TWiST by 2.42 months compared with chemotherapy alone. Conclusion: Compared with chemotherapy alone, trastuzumab plus chemotherapy prolongs time to deterioration of HRQoL and increases quality-adjusted survival in patients with HER2-positive gastric or gastroesophageal junction cancer. Abstract : This paper reports health-related quality of life (HRQoL) and quality-adjusted time without symptoms of disease or toxicity results from the ToGA (Trastuzumab for Gastric Cancer) phase III trial. Compared with chemotherapy alone, trastuzumab plus chemotherapy prolongs time to deterioration of HRQoL and increases quality-adjusted survival in patients with HER2-positive gastric or gastroesophageal junction cancer.